Tags

Type your tag names separated by a space and hit enter

Immune-mediated neuropathies.
Nat Rev Dis Primers. 2018 10 11; 4(1):31.NR

Abstract

Since the discovery of an acute monophasic paralysis, later coined Guillain-Barré syndrome, almost 100 years ago, and the discovery of chronic, steroid-responsive polyneuropathy 50 years ago, the spectrum of immune-mediated polyneuropathies has broadened, with various subtypes continuing to be identified, including chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy (MMN). In general, these disorders are speculated to be caused by autoimmunity to proteins located at the node of Ranvier or components of myelin of peripheral nerves, although disease-associated autoantibodies have not been identified for all disorders. Owing to the numerous subtypes of the immune-mediated neuropathies, making the right diagnosis in daily clinical practice is complicated. Moreover, treating these disorders, particularly their chronic variants, such as CIDP and MMN, poses a challenge. In general, management of these disorders includes immunotherapies, such as corticosteroids, intravenous immunoglobulin or plasma exchange. Improvements in clinical criteria and the emergence of more disease-specific immunotherapies should broaden the therapeutic options for these disabling diseases.

Authors+Show Affiliations

Department of Neurology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany. bernd.kieseier@uni-duesseldorf.de.Neuroinflammation Laboratory, Brain and Mind Centre, University of Sydney, Sydney, Australia.Department of Neurology, University of Würzburg, Würzburg, Germany.Department of Neurology, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

30310069

Citation

Kieseier, Bernd C., et al. "Immune-mediated Neuropathies." Nature Reviews. Disease Primers, vol. 4, no. 1, 2018, p. 31.
Kieseier BC, Mathey EK, Sommer C, et al. Immune-mediated neuropathies. Nat Rev Dis Primers. 2018;4(1):31.
Kieseier, B. C., Mathey, E. K., Sommer, C., & Hartung, H. P. (2018). Immune-mediated neuropathies. Nature Reviews. Disease Primers, 4(1), 31. https://doi.org/10.1038/s41572-018-0027-2
Kieseier BC, et al. Immune-mediated Neuropathies. Nat Rev Dis Primers. 2018 10 11;4(1):31. PubMed PMID: 30310069.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Immune-mediated neuropathies. AU - Kieseier,Bernd C, AU - Mathey,Emily K, AU - Sommer,Claudia, AU - Hartung,Hans-Peter, Y1 - 2018/10/11/ PY - 2018/10/13/entrez PY - 2018/10/13/pubmed PY - 2019/9/26/medline SP - 31 EP - 31 JF - Nature reviews. Disease primers JO - Nat Rev Dis Primers VL - 4 IS - 1 N2 - Since the discovery of an acute monophasic paralysis, later coined Guillain-Barré syndrome, almost 100 years ago, and the discovery of chronic, steroid-responsive polyneuropathy 50 years ago, the spectrum of immune-mediated polyneuropathies has broadened, with various subtypes continuing to be identified, including chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy (MMN). In general, these disorders are speculated to be caused by autoimmunity to proteins located at the node of Ranvier or components of myelin of peripheral nerves, although disease-associated autoantibodies have not been identified for all disorders. Owing to the numerous subtypes of the immune-mediated neuropathies, making the right diagnosis in daily clinical practice is complicated. Moreover, treating these disorders, particularly their chronic variants, such as CIDP and MMN, poses a challenge. In general, management of these disorders includes immunotherapies, such as corticosteroids, intravenous immunoglobulin or plasma exchange. Improvements in clinical criteria and the emergence of more disease-specific immunotherapies should broaden the therapeutic options for these disabling diseases. SN - 2056-676X UR - https://www.unboundmedicine.com/medline/citation/30310069/Immune_mediated_neuropathies_ L2 - http://dx.doi.org/10.1038/s41572-018-0027-2 DB - PRIME DP - Unbound Medicine ER -